Obesity drug DA-1726 tested in humans for first time
NCT ID NCT06252220
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called DA-1726 in 139 people with obesity. The main goal is to check safety and side effects. Researchers will also measure how the drug moves through the body and its effect on weight. Participants receive either the drug or a placebo, and neither they nor the doctors know who gets what.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DA-1726
What this could lead to
If successful, this could lead to a new weight-loss medication for people with obesity.
What could go wrong
This is a very early Phase 1 trial focused on safety, not effectiveness. The drug may not work or could have side effects. Results are years away.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Pharmacology of Miami, LLC
RECRUITINGMiami, Florida, 33172, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••